Compare Kinross Gold Corporation (KGC) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Organon & Co. Common Stock — how do they compare? Kinross Gold Corporation trades at $22.71 (market cap $26.40B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Kinross Gold Corporation is far larger — about 7.3× Organon & Co. Common Stock's market cap, and Kinross Gold Corporation pays the higher dividend (0.72%). Which is the better fit depends on your goals — on Pluang, investors hold Kinross Gold Corporation for 53 Days and Organon & Co. Common Stock for 0 Days on average.
| KGC | OGN | |
|---|---|---|
Market Cap | $26.40B | $3.61B |
Volume | 10,366,257 | 1,808,049 |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $13.81 |
52-Week Low | $22.24 | $5.70 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $24.48B | $11.03B |
Dividend Yield | 0.72% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $23.44, down 0.47% on the day, amid a bearish technical signal despite strong fundamental performance. The company reported robust earnings beats in recent quarters with Q2 2026 EPS of $0.71 exceeding expectations, while revenue grew to $7.05 billion in 2025. However, recent news highlights production guidance cuts for 2026-2027 and ongoing legal investigations, creating mixed sentiment. Technical indicators show the stock trading near key support at $23 with RSI levels suggesting potential oversold conditions.
KGC presents a compelling value opportunity with attractive valuation multiples (P/E 8.91, EV/EBITDA 4.6) and strong profitability margins (net income margin 37.52%). The company's increasing cash flow generation and shareholder return framework support upside potential toward the $38.80 consensus price target. Key risks include production challenges at key mines, rising operating costs, and legal uncertainties that could pressure near-term performance despite the positive long-term gold price environment.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
